Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03931785 · ClinicalTrials.gov registry record · Phase 2
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 515
- Enrollment target
NCT03931785: Completed Phase 2 study, sponsored by Ironwood Pharmaceuticals.
NCT03931785 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 515 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (287% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03931785, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 515 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Primary Outcome
Abdominal pain is measured daily in an eDiary, using an 11-point NRS, where 0 is anchored with "no abdominal pain" and 10 is anchored with "worst possible abdominal pain." The postbaseline weekly abdominal pain score is the average of the non-missing daily abdominal pain at its worst scores during a week (Weeks 1-12) if there are at least 4 daily scores entered into the eDiary during the week. Weekly change from baseline was calculated for each week as the weekly score minus the baseline score.
Interventions
- DRUG Placebo
- DRUG MD-7246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2020-03-11 |
| Phase | Phase 2 |
What the finished NCT03931785 record still lists
NCT03931785 is an interventional study that assigns participants to a tested intervention. The registered 515 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (287% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03931785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03931785 about?
NCT03931785 is a clinical study titled "A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome". To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
What is the current status of trial NCT03931785?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 515 participants. The study started on 2019-05-01. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT03931785?
The interventions under investigation include: Placebo (DRUG), MD-7246 (DRUG).
Who is sponsoring clinical trial NCT03931785?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03931785's enrollment target sits among peer trials
515 67th of 2000 higher than 1,934 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- NCT06804837 · 515 participants · NA
Implement and Test Visual Consent Template and Process
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI